1-(3,4-dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine,
BRL 52537,
BRL-52537,
BRL52537,
BRL 52537 hydrochloride,
130497-33-5,
2-(3,4-Dichlorophenyl)-1-(2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone hydrochloride,
112282-24-3,
BRL 52537,
Brl 52537 HCl,
AK-57392,
(+/-)-1-(3,4-Dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine hydrochloride,
2-(3,4-DICHLOROPHENYL)-1-(2-(PYRROLIDIN-1-YLMETHYL)PIPERIDIN-1-YL)ETHANONE HCL,
SR-01000076141,
EU-0101141,
BRL-52537 hydrochloride,
MLS002153457,
SCHEMBL8435659,
CHEMBL1256835,
CTK8C4721,
KS-00000FTT,
DTXSID00462129,
BCP21081,
EBD29079,
Tox21_501141,
ABP001017,
ANW-72902,
BN0592,
MFCD00672679,
AKOS015910291,
API0009081,
DS-1689,
LP01141,
MP-1898,
KS-000024N2,
NCGC00094407-01,
NCGC00261826-01,
4CA-0320,
BR-57392,
QC-10222,
SMR000326905,
AB0069170,
AX8118701,
RT-011816,
ST24027492,
B 5559,
J-005817,
SR-01000076141-1,
SR-01000076141-3,
I14-40265,
(+/-)-1-(3,4-Dichlorophenyl)acetyl-2-( 1-pyrrolidinyl)methylpiperidine hydrochloride,
2-(3,4-dichlorophenyl)-1-(2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethan-1-one hydrochloride,
2-(3,4-dichlorophenyl)-1-{2-[(pyrrolidin-1-yl)methyl]piperidin-1-yl}ethan-1-one hydrochloride,
cc-122,
D03QZJ,
D04YNW,
CC-122 HCl,
BRL-52537,
CID11315337,
CC-16057,
Pleiotropic pathway modulator (oral, cancer), Celgene,
Pleiotropic pathway modifiers (inflammatory disease), Celgene,